Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Outlook Therapeutics (OTLK) over the last 5 years, with Q4 2025 value amounting to $1.0 million.

  • Outlook Therapeutics' Other Accumulated Expenses rose 27827.47% to $1.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 million, marking a year-over-year increase of 27827.47%. This contributed to the annual value of $1.2 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Outlook Therapeutics reported Other Accumulated Expenses of $1.0 million as of Q4 2025, which was up 27827.47% from $1.2 million recorded in Q3 2025.
  • In the past 5 years, Outlook Therapeutics' Other Accumulated Expenses ranged from a high of $1.3 million in Q2 2025 and a low of $276958.0 during Q4 2024